文献速递腹部MR

混合型肝细胞癌-胆管癌的MRI特征与肿瘤生物标志物及预后的相关性

Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.
PubMed 文献 · Eur Radiol · 2021-07-19

本研究回顾性纳入160例经2019 WHO分类病理确诊的cHCC-CCA患者,评估术前MRI特征与AFP或CA19-9水平及病理表现的相关性,并分析RFS和OS的预测因素。结果显示影像特征复杂且与AFP或CA19-9不相关;年龄、CA19-9>37 U/ml、动脉期瘤周强化和延迟强化是RFS不良的独立预测因素,动脉期周边强化是OS不良的独立预测因素。

要点

  • cHCC-CCA的MRI特征复杂,与AFP或CA19-9水平不相关。
  • 动脉期瘤周强化和延迟强化是RFS不良的独立预测因素。
  • 动脉期周边强化是OS不良的独立预测因素。

关键影像表现/征象

  • 结节套结节架构、马赛克架构、瘤内出血、肝包膜回缩、动脉期瘤周强化和门静脉癌栓在AFP>20 ng/ml患者中发生率显著更高(均p<0.05)。

诊断标准与关键数值

  • AFP>20 ng/ml患者中结节套结节架构、马赛克架构、瘤内出血、肝包膜回缩、动脉期瘤周强化和门静脉癌栓发生率显著更高(均p<0.05)。
  • 多因素Cox回归显示年龄(HR 1.031,p=0.03)、CA19-9>37 U/ml(HR 1.880,p=0.04)、动脉期瘤周强化(HR 2.287,p=0.01)和延迟强化(HR 0.377,p=0.02)是RFS不良的独立预测因素。
  • 动脉期周边强化(HR 2.391,p=0.04)是OS不良的独立预测因素。

临床应用与阅片要点

  • 阅片时注意评估结节套结节架构、马赛克架构、瘤内出血、肝包膜回缩、动脉期瘤周强化和门静脉癌栓等特征。
  • 报告时可提示动脉期瘤周强化、延迟强化和动脉期周边强化等预后相关影像特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine how MRI features are correlated to biomarkers, and to the prognostic factors for recurrence-free survival (RFS) and overall survival (OS) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) patients.

METHODS: The study enrolled 160 cHCC-CCA patients pathologically confirmed according to the 2019 WHO classification. The preoperative MRI features and clinical data were retrospectively evaluated and compared between patients grouped by AFP or CA19-9 level and with pathological findings. The RFS and OS of cHCC-CCA patients were estimated using Kaplan-Meier survival curves and compared using the log-rank test. Moreover, predictors of RFS and OS were investigated using Cox regression analyses.

RESULTS: One hundred and sixty patients (mean age, males vs. females: 55.7 ± 10.2 years vs. 54.9 ± 14.0 years) were evaluated. The incidence of nodule-in-nodule architecture, mosaic architecture, intratumoral hemorrhage, hepatic capsule retraction, arterial phase peritumoral enhancement, and portal vein thrombus was significantly higher in patients with AFP > 20 ng/ml (all p < 0.05). Multivariate Cox regression analysis indicated that age (HR 1.031, p = 0.03), CA19-9 > 37 U/ml (HR 1.880, p = 0.04), arterial phase peritumoral enhancement (HR 2.287, p = 0.01), and delayed enhancement (HR 0.377, p = 0.02) were independent predictors of poor RFS, while arterial phase peripheral enhancement (HR 2.391, p = 0.04) was an independent predictor of poor OS.

CONCLUSIONS: cHCC-CCA imaging features are complex and not correlated with AFP or CA19-9. Age, CA19-9 > 37 U/ml, arterial phase peritumoral enhancement, and delayed enhancement are independent predictors of poor RFS. Arterial phase peripheral enhancement is an independent predictor of poor OS.

KEY POINTS: • The imaging features of combined hepatocellular carcinoma-cholangiocarcinoma are complex and are not correlated with the alpha fetoprotein or CA19-9 levels. • Age, CA19-9 > 37 U/ml, arterial phase peritumoral enhancement, and delayed enhancement are independent predictors of poor recurrence-free survival in combined hepatocellular carcinoma-cholangiocarcinoma patients. • Arterial phase peripheral enhancement is an independent predictor of poor overall survival in patients with combined hepatocellular carcinoma-cholangiocarcinoma.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Wang Y, Ma L, et al. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol. 2021. PMID: 34279688. doi:10.1007/s00330-021-08188-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。